EGFR-targeting agents in oncology

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 8, 2008, Pages 889-901

  Garofalo, Sonia ^a   Rosa, Roberta ^a   Bianco, Roberto ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

EGFR; HER; Monoclonal antibody; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMC 225; IRINOTECAN; MATUZUMAB; NAVELBINE; PANITUMUMAB; PF 00299804; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; VANDETANIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; PANCREAS CANCER; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 51049115089     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.8.889     Document Type: Review

References (138)

1. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-72
2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59
3. Arena S, Benvenuti S, Bardelli A. Genetic analysis of the kinome and phosphatome in cancer. Cell Mol Life Sci 2005;62:2092-9
4. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52
5. De Larco JE, Reynolds R, Carlberg K, et al. Sarcoma growth factor from mouse sarcoma virus transformed cells. Purification by binding and elution from epidermal growth factor receptor-rich cells. J Biol Chem 1980;255:3685-90
6. Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-7
7. Bianco R, Gelardi T, Damiano V, et al. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 2007;39:1416-31
8. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7:2-8
9. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16
10. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001;8:3-9
11. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994;19:459-63
12. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:3-8
13. Normanno N, Bianco C, De Luca A, et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003;10:11-21
14. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 1996;271:6071-6
15. Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF related peptides in tumor growth. Front Biosci 2001;6:685-707
16. Sebastian S, Settleman J, Reshkin SJ, et al. The complexity of targeting EGFR signalling in cencer: from expression to turnover. Biochim Biophys Acta 2006;1766:120-39
17. Ferguson KM. Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 2004;32:742-5
18. Stover DR, Becker M, Liebetanz J, Lydon NB. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem 1995;270:15591-7
19. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci USA 1999;96:4240-5
20. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001;264:29-41
21. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82
22. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71
23. Lowenstein EJ, Daly RJ, Barzer AG, et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signalling. Cell 1992;70:431-42
24. Marais R, Marshall CJ. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv 1996;27:101-25
25. Johnson GL, Dohlman HG, Graves LM. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr Opin Chem Biol 2005;9:325-31
26. Patterson RL, van Rossum DB, Nikolaidis N, et al. Phospholipase C-g: diverse roles in receptor mediated calcium signaling. Trends Biochem Sci 2005;30:688-97
27. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998;18:790-8
28. Murphy LO, Smith S, Chen RH, et al. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 2002;4:556-64
29. Andl CD, Mizushima T, Oyama K, et al. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol 2004;287:1227-37
30. Bromberg J. Stat proteins andoncogenesis. J Clin Invest 2002;109:1139-42
31. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87-98
32. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37:S9-15
33. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
34. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991;9:553-62
35. Ohgaki H. Genetic pathways to glioblastoma. Neuropathology 2005;25:1-7
36. Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al. Epidermal growth factor receptor and cyclist D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005;131:111-9
37. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89:4309-13
38. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96
39. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-9
40. Nishikawa R, Ji XD, Harmon RC, et al. Amutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-31
41. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
42. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-95
43. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73
44. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44
45. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33
46. O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 2000;18:155-61
47. Ciardiello F, Caputo R, Troiani T, et al. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 2001;15:172-8
48. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-43
49. Liu Z, Li H, Derouet M, et al. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem 2005;280:37383-92
50. Benoit VA, Chariot L, Delacroix V, et al. Bours, Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor alpha stimulation is counteracted by nuclear factor kappaB through c-FLIP-L expression. Cancer Res 2004;64:2684
51. Stoll SW, Benedict M, Mitra R, et al. EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-XL. Oncogene 1998;16:1493-9
52. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004;64:5078-83
53. Friday BB, Adjei AA. K-ras ass target for cancer therapy. Biochim Biophys Acta 2005;1756:127-44
54. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003;22:2812-22
55. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3-kinase/Akt pathway signaling. Clin Cancer Res 2003;9:4340-6
56. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2005;18:449-55
57. Schlessinger J, Givol D (IL), Bellot F, et al. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same. US6217866; 2001
58. Beidler CE, Vasserot AP, Watkins JD, et al. Anti-EGFR antibodies. WO2007058823; 2007
59. Schnur RC, Arnold LD. Alkynyl and azido-substituted 4-anilinoquinazolines. US5747498; 1998
60. Tung R. 4-Aminoquinazoline derivatives and methods of use thereof. US2008051422; 2008
61. Azemar M, Schmidt M, Arlt F, et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 2000;86:269-75
62. Sun LE. Immunoconjugates with improved efficacy for the treatment of diseases. US2007196274; 2007
63. Laeremans T, De haard H, Hoogenboom HRJ, et al. Nanobodies and polypeptides against EGFR and IGF-1R. WO2007042289; 2007
64. Yamazaki H, Kijima H, Ohnishi Y, et al. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 1998;90:581-7
65. Steinaa L, Renard V. Immunogenic EGFR peptides comprising foreign T cell stimulating epitope. EP1874332; 2008
66. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004;173:4699-707
67. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
68. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13
69. Hadari YR, Doody JF, Wang Y, et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor [abstract 234]. ASCO Annual Meeting 2004; 5-8 June 2004; New Orleans, Louisiana, USA
70. Peng D, Fan Z, Lu Y, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-9
71. Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. EGF receptor antibody downregulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 2006;281:40183-92
72. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65
73. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with tpotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16
74. Aventis Holdings, Inc., Imclone Systems, Inc. Cetuximab in combination with irinotecan. EP0667165: 2004
75. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007;120:781-7
76. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-90
77. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40
78. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14
79. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
80. Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer 2007;6:S42-6
81. Merlano M, Occelli M. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag 2007;3:871-6
82. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008;20:162-75
83. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF,a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23
84. Yang XD, Jia XC, Corvalan J, et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment [abstract 183]. ASCO Annual Meeting 2000; 19 - 23 May 2000; New Orleans, Louisiana
85. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-8
86. Schwartz G, Dutcher JP, Vogelzang NJ, et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC) [abstract 91]. ASCO Annual Meeting 2002; 18 - 21 May 2002; Orlando, Florida, USA
87. Gillies SD, Azria D, Larbouret C, Pelegrin A. Combination therapy using anti-EGFR and anti-HER2 antibodies. WO2007076923; 2007
88. Schiller JH. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000). Cancer Invest 2008;26:81-95
89. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol 2008;47:9-19
90. Friedländer E, Barok M, Szöllosi, et al. ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett 2008;116:126-40
91. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007;104:4071-6
92. Chul JS, Kim D-H, Park HH, et al. Humanized monoclonal antibody highly binding to Epidermal Growth Factor Receptor. WO2008004834; 2008
93. Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs 2000;60:33-40
94. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63
95. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92
96. Wedge SR. Cancer combination therapy comprising AZD2171 and ZD1839. WO2005004872; 2005
97. Ryan AJ. Combination therapy for the treatment of cancer. WO03088971; 2003
98. Wedge SR. Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer. WO2004014426; 2004
99. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
100. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2004;21:2237-46
101. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-9
102. Chen J, Higgins B, Kolinsky K, et al. Treatment with irinotecan (CPT-11) and an EGFR-inhibitor. WO2005117877; 2005
103. Chen J, Higgins B, Kolinsky K, et al. Treatment with oxaliplatin and an EGFR-inhibitor. WO2005117915; 2005
104. Higgins B, Kolinsky K. Treatment with gemcitabine and an EGFR-inhibitor. WO2005117887; 2005
105. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48
106. Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-6
107. Gridelli C, Bareschino MA, Schettino C, et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007;12:840-9
108. Heeger S. Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer. Rec Res Cancer Res 2008;177:131-6
109. Nyati MK, Maheshwari D, Hanasoge S, et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004;10:691-700
110. Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 2002;21:2407-17
111. Jänne PA, von Pawel J, Cohen RB. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007;25:3936-44
112. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32
113. Ryan AJ. Combination of ZD6474 and Bevacizumab for cancer therapy. WO2008037996; 2008
114. Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 2007;13:s4617-22
115. Soles F. Method for treating cancer harbouring EGFR mutations. WO2008034776; 2008
116. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; [Epub ahead of print]
117. Bilancia D, Rosati G, Dinota A, et al. Lapatinib in breast cancer. Ann Oncol 2007;18:vi26-30
118. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74
119. Green TP. Combination product comprising Src kinase inhibitor AZD0530 and an anti-oestrogen or EGFR-TK inhibitor. WO2005117888; 2005
120. Harari PM, Chinnaiyan P, Huang SJ. Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor. WO2006110176; 2006
121. Piperdi B. Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor. WO2006110175; 2006
122. Garcia MV, Bunn PA, Cappuzzo F, et al. Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients. US2008090233; 2008
123. Bunn PA, Coldren CD, Franklin WA, et al. Gefitinib sensitivity-related gene expression and products and methods related thereto. US2007270505; 2007
124. Hillan KJ. EGFR and K-Ras mutations. EP1913157; 2008
125. Haley JD, Thomson S, Petti F. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors. US2007212738; 2007
126. Shibata T, et al. Method for measuring sensitivity of pulmonary cancer to epidermal growth factor receptor-tyrosine kinase inhibitor and method for screening pulmonary cancer treating agents. JP2007252312; 2007
127. Ford SK, Hanada J. Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer. US2007259375; 2007
128. Seshagiri S. EGFR mutations. EP1766068; 2007
129. Bell DW, Haber DA, Janne PA, et al. Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments. US2008096212; 2008
130. Siena S, Moroni M, Marrapese G, et al. Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues. WO2006108627; 2006
131. Tortora G, Bianco R, Daniele G, et al. Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 2007;10:81-100
132. Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8
133. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-9
134. Volante M, Saviozzi S, Rapa I, et al. Epidermal growth factor ligand/ receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer 2007;110:1321-8
135. Chang D. Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors. US2006216288; 2006
136. Sieger S, Berndorff D, Dinkelborg L, et al. Combination of an anti-EDB fibronectin domain antibody L19-SIP, and an anti-EGFR antibody. WO2007128557; 2007
137. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-96
138. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55